It was reported a patient underwent an idiopathic ventricular tachycardia (idvt) ablation procedure with a thermocool® smart touch® sf bi-directional navigation catheter and patient experienced cardiac tamponade treated with a pericardiocentesis and hospitalization in intensive care unit for observation.Transseptal puncture occurred.They attempted to map with an optrell catheter and could not get it through the mitral valve.The physician switched to a deca nav catheter and was able to get it into the left ventricle.The ablation catheter was placed into the patient and they performed two ablations, the patient took really deep breaths, and the physician discovered and confirmed an effusion using ice and fluoroscopy.All catheters were removed.No negative patient symptoms were present.As medical intervention they "reversed the anti-coagulation, followed by performing a pericardiocentesis" and 435 cc's of fluid was removed and the patient was stabilized.The patient was transferred to intensive care unit (icu).Additional information received indicated the correct catheter settings were utilized and no error messages occurred on the equipment during the procedure.The patient has fully recovered.
|
Device investigation details: the device has been reported as discarded, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A manufacturing record evaluation was performed for the finished device 31142773l number, and no internal action related to the complaint was found during the review.As part of our company quality system process, all devices are manufactured, inspected, and distributed to approved specifications.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|